Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.

Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, Olson MP, Molinaro AM, Berger MS, Kurhanewicz J, Ronen SM, Chang SM, Nelson SJ.

Sci Rep. 2017 Mar 22;7:44792. doi: 10.1038/srep44792.

2.

Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.

Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H.

Neurosurg Focus. 2015 Mar;38(3):E2. doi: 10.3171/2015.1.FOCUS14745. Review.

PMID:
25727224
3.

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D.

Neuro Oncol. 2013 Jun;15(6):682-90. doi: 10.1093/neuonc/not006. Epub 2013 Feb 14.

4.

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

Andronesi OC, Loebel F, Bogner W, Marjańska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP.

Clin Cancer Res. 2016 Apr 1;22(7):1632-41. doi: 10.1158/1078-0432.CCR-15-0656. Epub 2015 Nov 3.

5.

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.

Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG.

Sci Transl Med. 2012 Jan 11;4(116):116ra4. doi: 10.1126/scitranslmed.3002693.

6.

Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.

Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HAI, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ.

Sci Transl Med. 2012 Jan 11;4(116):116ra5. doi: 10.1126/scitranslmed.3002796.

7.

Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.

Nagashima H, Tanaka K, Sasayama T, Irino Y, Sato N, Takeuchi Y, Kyotani K, Mukasa A, Mizukawa K, Sakata J, Yamamoto Y, Hosoda K, Itoh T, Sasaki R, Kohmura E.

Neuro Oncol. 2016 Nov;18(11):1559-1568. Epub 2016 May 5.

8.

Characterization of metabolites in infiltrating gliomas using ex vivo ¹H high-resolution magic angle spinning spectroscopy.

Elkhaled A, Jalbert L, Constantin A, Yoshihara HA, Phillips JJ, Molinaro AM, Chang SM, Nelson SJ.

NMR Biomed. 2014 May;27(5):578-93. doi: 10.1002/nbm.3097. Epub 2014 Mar 5.

9.

In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.

Kim H, Kim S, Lee HH, Heo H.

Korean J Radiol. 2016 Sep-Oct;17(5):620-32. doi: 10.3348/kjr.2016.17.5.620. Epub 2016 Aug 23. Review.

10.

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.

Han CH, Batchelor TT.

Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11.

11.

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA.

Nat Med. 2012 Jan 26;18(4):624-9. doi: 10.1038/nm.2682.

12.

[Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].

Pan Y, Qi XL, Wang LM, Dong RF, Zhang M, Zheng DF, Chang Q, Zhong YF.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):292-8. doi: 10.3760/cma.j.issn.0529-5807.2013.05.002. Chinese.

PMID:
24004584
13.

Glioma-derived mutations in IDH: from mechanism to potential therapy.

Fu Y, Huang R, Du J, Yang R, An N, Liang A.

Biochem Biophys Res Commun. 2010 Jun 25;397(2):127-30. doi: 10.1016/j.bbrc.2010.05.115. Epub 2010 May 27. Review.

PMID:
20510884
14.

A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma.

Ohka F, Yamamichi A, Kurimoto M, Motomura K, Tanahashi K, Suzuki H, Aoki K, Deguchi S, Chalise L, Hirano M, Kato A, Nishimura Y, Hara M, Kato Y, Wakabayashi T, Natsume A.

Brain Tumor Pathol. 2017 Apr;34(2):91-97. doi: 10.1007/s10014-017-0281-0. Epub 2017 Mar 28.

PMID:
28353033
15.

Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.

Natsumeda M, Igarashi H, Nomura T, Ogura R, Tsukamoto Y, Kobayashi T, Aoki H, Okamoto K, Kakita A, Takahashi H, Nakada T, Fujii Y.

Acta Neuropathol Commun. 2014 Nov 7;2:158. doi: 10.1186/s40478-014-0158-y.

16.

Magnetic resonance metabolic imaging of glioma.

Metellus P, Figarella-Branger D.

Sci Transl Med. 2012 Jan 11;4(116):116ps1. doi: 10.1126/scitranslmed.3003591.

PMID:
22238331
17.

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.

Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, Rosell R, Villà S, Diaz R, Estival A, Teixidor P, Indacochea A, Ahjal S, Vilà L, Balañá C.

J Neurooncol. 2017 Nov;135(2):273-284. doi: 10.1007/s11060-017-2570-1. Epub 2017 Sep 7.

PMID:
28884377
18.

[Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].

Liu QQ, Yin XX, Zou Y, Yu TP, Gong J, Chen XQ, Nie L, Xu M, Zhang MN, Zhou Q, Chen N.

Zhonghua Bing Li Xue Za Zhi. 2018 Sep 8;47(9):658-663. doi: 10.3760/cma.j.issn.0529-5807.2018.09.002. Chinese.

PMID:
30220117
19.

MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.

Stadlbauer A, Zimmermann M, Kitzwögerer M, Oberndorfer S, Rössler K, Dörfler A, Buchfelder M, Heinz G.

Radiology. 2017 Jun;283(3):799-809. doi: 10.1148/radiol.2016161422. Epub 2016 Dec 13.

PMID:
27982759
20.

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.

de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB.

Neuro Oncol. 2016 Feb;18(2):283-90. doi: 10.1093/neuonc/nov307. Epub 2015 Dec 20.

Supplemental Content

Support Center